Nω-Propyl-L-arginine hydrochlorideCAS# 137361-05-8 |
- SU14813
Catalog No.:BCC1971
CAS No.:627908-92-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 137361-05-8 | SDF | Download SDF |
| PubChem ID | 447180 | Appearance | Powder |
| Formula | C9H20N4O2 | M.Wt | 216.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in water and to 100 mM in DMSO | ||
| Chemical Name | (2S)-2-amino-5-[(N'-propylcarbamimidoyl)amino]pentanoic acid | ||
| SMILES | CCCN=C(N)NCCCC(C(=O)O)N | ||
| Standard InChIKey | AOMXURITGZJPKB-ZETCQYMHSA-N | ||
| Standard InChI | InChI=1S/C9H20N4O2/c1-2-5-12-9(11)13-6-3-4-7(10)8(14)15/h7H,2-6,10H2,1H3,(H,14,15)(H3,11,12,13)/t7-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Highly selective and potent inhibitor of nNOS (Ki = 57 nM). Displays 3158-fold and 149-fold selectivity over iNOS and eNOS respectively. Hypotensive in vivo. |
Nω-Propyl-L-arginine hydrochloride Dilution Calculator
Nω-Propyl-L-arginine hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.6232 mL | 23.116 mL | 46.2321 mL | 92.4642 mL | 115.5802 mL |
| 5 mM | 0.9246 mL | 4.6232 mL | 9.2464 mL | 18.4928 mL | 23.116 mL |
| 10 mM | 0.4623 mL | 2.3116 mL | 4.6232 mL | 9.2464 mL | 11.558 mL |
| 50 mM | 0.0925 mL | 0.4623 mL | 0.9246 mL | 1.8493 mL | 2.3116 mL |
| 100 mM | 0.0462 mL | 0.2312 mL | 0.4623 mL | 0.9246 mL | 1.1558 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- GSK J4 HCl
Catalog No.:BCC2230
CAS No.:1373423-53-0
- GSK J1
Catalog No.:BCC2231
CAS No.:1373422-53-7
- Boc-Val-OH
Catalog No.:BCC3465
CAS No.:13734-41-3
- Boc-Thr(tBu)-OH
Catalog No.:BCC3452
CAS No.:13734-40-2
- Boc-Ser(tBu)-OH
Catalog No.:BCC3444
CAS No.:13734-38-8
- Boc-Sar-OH
Catalog No.:BCC3337
CAS No.:13734-36-6
- Boc-Phe-OH
Catalog No.:BCC3432
CAS No.:13734-34-4
- Boc-Lys-OH
Catalog No.:BCC3410
CAS No.:13734-28-6
- Thrombin Receptor Agonist Peptide
Catalog No.:BCC3950
CAS No.:137339-65-2
- LY 215840
Catalog No.:BCC7101
CAS No.:137328-52-0
- Cathepsin S inhibitor
Catalog No.:BCC1455
CAS No.:1373215-15-6
- Dehydroeffusol
Catalog No.:BCN2927
CAS No.:137319-34-7
- PF-5274857
Catalog No.:BCC3838
CAS No.:1373615-35-0
- Spathulatol
Catalog No.:BCN6877
CAS No.:1373888-27-7
- Diacerein
Catalog No.:BCN2291
CAS No.:13739-02-1
- 15,16-Epoxy-15-ethoxy-6beta,13-dihydroxylabd-8-en-7-one
Catalog No.:BCN7428
CAS No.:1374328-47-8
- LY 235959
Catalog No.:BCC6892
CAS No.:137433-06-8
- TUG 891
Catalog No.:BCC6235
CAS No.:1374516-07-0
- BRD4770
Catalog No.:BCC5525
CAS No.:1374601-40-7
- LEE011 succinate
Catalog No.:BCC4102
CAS No.:1374639-75-4
- LEE011 succinate hydrate
Catalog No.:BCC4103
CAS No.:1374639-79-8
- CO-1686 (AVL-301)
Catalog No.:BCC1490
CAS No.:1374640-70-6
- Rhapontisterone
Catalog No.:BCC8245
CAS No.:137476-71-2
- GNE0877
Catalog No.:BCC5369
CAS No.:1374828-69-9
The influence of nitric oxide synthase 1 on blood flow and interstitial nitric oxide in the kidney.[Pubmed:11404282]
Am J Physiol Regul Integr Comp Physiol. 2001 Jul;281(1):R91-7.
The role of nitric oxide (NO) produced by NO synthase 1 (NOS1) in the renal vasculature remains undetermined. In the present study, we investigated the influence of systemic inhibition of NOS1 by intravenous administration of N(omega)-propyl-L-arginine (L-NPA; 1 mg. kg(-1). h(-1)) and N(5)-(1-imino-3-butenyl)-L-ornithine (v-NIO; 1 mg. kg(-1). h(-1)), highly selective NOS1 inhibitors, on renal cortical and medullary blood flow and interstitial NO concentration in Sprague-Dawley rats. Arterial blood pressure was significantly decreased by administration of both NOS1-selective inhibitors (-11 +/- 1 mmHg with L-NPA and -7 +/- 1 mmHg with v-NIO; n = 9/group). Laser-Doppler flowmetry experiments demonstrated that blood flow in the renal cortex and medulla was not significantly altered following administration of either NOS1-selective inhibitor. In contrast, the renal interstitial level of NO assessed by an in vivo microdialysis oxyhemoglobin-trapping technique was significantly decreased in both the renal cortex (by 36-42%) and medulla (by 32-40%) following administration of L-NPA (n = 8) or v-NIO (n = 8). Subsequent infusion of the nonspecific NOS inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME; 50 mg. kg(-1). h(-1)) to rats pretreated with either of the NOS1-selective inhibitors significantly increased mean arterial pressure by 38-45 mmHg and significantly decreased cortical (25-29%) and medullary (37-43%) blood flow. In addition, L-NAME further decreased NO in the renal cortex (73-77%) and medulla (62-71%). To determine if a 40% decrease in NO could alter renal blood flow, a lower dose of L-NAME (5 mg. kg(-1). h(-1); n = 8) was administered to a separate group of rats. The low dose of L-NAME reduced interstitial NO (cortex 39%, medulla 38%) and significantly decreased blood flow (cortex 23-24%, medulla 31-33%). These results suggest that NOS1 does not regulate basal blood flow in the renal cortex or medulla, despite the observation that a considerable portion of NO in the renal interstitial space appears to be produced by NOS1.
